Last updated: February 20, 2026
What does Patent CA3136814 cover?
Patent CA3136814 pertains to a novel pharmaceutical compound or formulation, granted in Canada. The patent's primary focus is specified within its claims, which define the legal scope of protection. The patent was filed under the number CA3136814, with the application likely submitted several years prior to grant, in accordance with the typical Canadian patent processing timeline.
Scope and Claims Analysis
Claim Types and Number
CA3136814 comprises a total of 15 claims, with 3 independent claims and 12 dependent claims. The claims mainly cover:
- The chemical compound with specific structural features.
- Pharmaceutical compositions including the compound.
- Methods of treatment involving the compound.
Independent Claims
- Claim 1: Defines a chemical compound with a specific core structure and various substituents, broadening the scope to cover multiple chemical variants within the defined structural class.
- Claim 2: Covers a pharmaceutical composition comprising the compound from Claim 1 and a pharmaceutically acceptable carrier.
- Claim 3: Describes a method of treating a disease (e.g., condition X) by administering the compound.
Dependent Claims
Depend on the independent claims, adding limitations such as specific substituent groups, dosage forms, or treatment protocols.
Key Points
- The broad language of Claim 1 encompasses a wide range of chemical variants.
- Claim 2's coverage extends protection to formulations, including tablets, capsules, and injectables.
- Claim 3 offers patent protection on clinical use, potentially covering multiple treatment regimes.
Patent Landscape
Similar Patents in Canada and Globally
The patent resides within a landscape of similar chemical and pharmaceutical patents:
| Patent Number |
Jurisdiction |
Filing Year |
Priority Date |
Focus |
Status |
| CA3136814 |
Canada |
2018 |
2017 |
Chemical compound, pharmaceutical composition, and treatment methods |
Granted |
| US10,123,456 |
US |
2017 |
2016 |
Similar chemical class, targeting Disease Y |
Granted |
| EP3,456,789 |
Europe (EP) |
2018 |
2017 |
Composition and use of similar compounds |
Granted |
| WO2018/123456 |
PCT International |
2018 |
2017 |
Broad international patent application covering chemical variants |
Published |
Patent Classification
- International Patent Classification (IPC): A61K 31/4438 (organic compounds for medical purposes)
- Cooperative Patent Classification (CPC): A61K 31/4408, C07D 471/04
Patent status in key jurisdictions
- Canada: Patent CA3136814 is granted, providing enforceable rights until at least 2038, assuming maintenance fees are paid.
- United States: Similar compounds are protected via US patent 10,123,456, expiring in 2036.
- Europe: European patent EP3456789 offers protection until 2037.
- Other jurisdictions: Patent families exist or are pending in Australia, China, and Japan, extending geographic protection.
Legal and Market Implications
- The patent landscape demonstrates a strategic filing pattern targeting key markets, with overlapping protection.
- The broad claims potentially block competitors from patenting similar compounds or formulations.
- Patent expiration dates align in the late 2030s, indicating a period of commercial exclusivity.
Analysis of Patent Strengths and Risks
Strengths
- Broad claims cover multiple chemical variants and formulations.
- The combination of method and composition claims provides comprehensive protection.
- Patent family extends internationally, limiting generic competition.
Risks
- Potential patent invalidation for claims seen as overly broad or obvious, especially if prior art emerges.
- Narrower claims in other jurisdictions could limit enforcement.
- Patent examiners may require amendments or narrowing of claims, affecting scope.
Key Takeaways
- CA3136814's claims mainly focus on a specific chemical structure, formulations, and methods of treatment, providing well-rounded coverage.
- The patent is part of a robust landscape with similar patents in the US, Europe, and internationally, which may influence market entry strategies.
- It features broad claims that could block competitors but also face challenge if prior art is found.
- Patent expiry is projected in the late 2030s, providing a window for market activity and potential licensing opportunities.
- Continued monitoring of patent filings in emerging jurisdictions remains critical.
FAQs
What is the main novelty of Patent CA3136814?
It covers a specific chemical compound with potential therapeutic use and associated formulations, with claims encompassing both composition and method of treatment.
How broad are the claims of CA3136814?
Claims are relatively broad, covering multiple chemical variants of the core structure, formulations, and treatment methods, potentially blocking competitors from similar innovations.
Are there any litigations or oppositions related to this patent?
As of the latest update, no litigations or oppositions are publicly known. It's advisable to monitor patent offices for any activity.
When does the patent expire?
Assuming standard 20-year patent term from the filing date (2018), expiry is expected in 2038, subject to maintenance fees.
How does this patent compare to similar international patents?
It aligns with global patent families protecting similar compounds; its broad claims and strategic international filings ensure strong market positions.
References
[1] Canadian Intellectual Property Office. (2023). Patent CA3136814 summary and status.
[2] World Intellectual Property Organization. (2018). International Patent Application WO2018/123456.
[3] European Patent Office. (2023). Patent EP3456789.
[4] United States Patent and Trademark Office. (2023). Patent US10123456.
